AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by equities research analysts at UBS Group in a research report issued on Monday, Borsen Zeitung reports. They currently have a GBX 5,400 ($70.56) price objective on the biopharmaceutical company’s stock. UBS Group’s price target would suggest a potential downside of 8.09% from the stock’s current price.
Several other research firms also recently weighed in on AZN. Deutsche Bank reissued a “buy” rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Monday, February 18th. Bryan, Garnier & Co downgraded AstraZeneca to a “neutral” rating in a report on Friday, February 22nd. Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca and gave the company a “sell” rating in a report on Tuesday, May 7th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, April 10th. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Thursday, February 14th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 6,397.70 ($83.60).
Shares of AZN stock traded down GBX 5 ($0.07) during trading hours on Monday, reaching GBX 5,875 ($76.77). The company’s stock had a trading volume of 1,232,891 shares, compared to its average volume of 2,310,000. The company has a market cap of $77.07 billion and a PE ratio of 30.92. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46). The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Reverse Stock Split
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.